<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33789997</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>24</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Antiviral Peptides Targeting the Helicase Activity of Enterovirus Nonstructural Protein 2C.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e02324-20</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.02324-20</ELocationID><Abstract><AbstractText>Enteroviruses belong to the genus <i>Enterovirus</i> of the family <i>Picornaviridae</i> and include four human enterovirus groups (EV-A to -D): the epidemic of enteroviruses such as human enterovirus A71 (EV-A71) and coxsackievirus A16 (CVA16) is a threat to global public health. Enteroviral protein 2C is the most conserved nonstructural protein among all enteroviruses and possesses RNA helicase activity that plays pivotal roles during enteroviral life cycles, which makes 2C an attractive target for developing antienterovirus drugs. In this study, we designed a peptide, named 2CL, based on the structure of EV-A71 2C. This peptide effectively impaired the oligomerization of EV-A71 2C protein and inhibited the RNA helicase activities of 2C proteins encoded by EV-A71 and CVA16, both of which belong to EV-A, and showed potent antiviral efficacy against EV-A71 and CVA16 in cells. Moreover, the 2CL treatment elicited a strong <i>in vivo</i> protective efficacy against lethal EV-A71 challenge. In addition, the antiviral strategy of targeting the 2C helicase activity can be applied to inhibit the replication of EV-B. Either 2CL or B-2CL, the peptide redesigned based on the 2CL-corresponding sequence of EV-Bs, could exert effective antiviral activity against two important EV-Bs, coxsackievirus B3 and echovirus 11. Together, our findings demonstrated that targeting the helicase activity of 2C with a rationally designed peptide is an efficient antiviral strategy against enteroviruses, and 2CL and B-2CL show promising clinical potential to be further developed as broad-spectrum antienterovirus drugs.<b>IMPORTANCE</b> Enteroviruses are a large group of positive-sense single-stranded RNA viruses and include numerous human pathogens, such as enterovirus A71 (EV-A71), coxsackieviruses, and echoviruses. However, no approved EV antiviral drugs are available. Enteroviral 2C is the most conserved nonstructural protein among all enteroviruses and contains the RNA helicase activity critical for the viral life cycle. Herein, according to the structure of EV-A71 2C, we designed a peptide that effectively inhibited the RNA helicase activities of EV-A71- and coxsackievirus A16 (CVA16)-encoded 2C proteins. Moreover, this peptide exerted potent antiviral effects against EV-A71 and CVA16 in cells and elicited therapeutic efficacy against lethal EV-A71 challenge <i>in vivo</i> Furthermore, we demonstrate that the strategy of targeting the 2C helicase activity can be used for other relevant enteroviruses, including coxsackievirus B3 and echovirus 11. In summary, our findings provide compelling evidence that the designed peptides targeting the helicase activity of 2C could be broad-spectrum antivirals for enteroviruses.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 American Society for Microbiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Ruyi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xue-Yi</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xi</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-3846-5079</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China zhouxi@wh.iov.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C076023">2C protein, viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D020365">RNA Helicases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020365" MajorTopicYN="N">RNA Helicases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antimicrobial peptides</Keyword><Keyword MajorTopicYN="N">antiviral agents</Keyword><Keyword MajorTopicYN="N">enteroviral 2C</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">helicase</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>1</Day><Hour>5</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33789997</ArticleId><ArticleId IdType="pmc">PMC8315976</ArticleId><ArticleId IdType="doi">10.1128/JVI.02324-20</ArticleId><ArticleId IdType="pii">JVI.02324-20</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pallansch MA. 2007. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, p 840&#x2013;893. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams &amp; Wilkins, Philadelphia, PA.</Citation></Reference><Reference><Citation>Yun SH, Lee WG, Kim YC, Ju ES, Lim BK, Choi JO, Kim DK, Jeon ES. 2012. Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis. J Infect Dis 205:491&#x2013;497. 10.1093/infdis/jir745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir745</ArticleId><ArticleId IdType="pubmed">22207647</ArticleId></ArticleIdList></Reference><Reference><Citation>Baboonian C, Davies MJ, Booth JC, McKenna WJ. 1997. Coxsackie B viruses and human heart disease. Curr Top Microbiol Immunol 223:31&#x2013;52. 10.1007/978-3-642-60687-8_3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-60687-8_3</ArticleId><ArticleId IdType="pubmed">9294924</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskowitz A, Beisel KW, Wolfgram LJ, Rose NR. 1985. Coxsackievirus B3 murine myocarditis: wide pathologic spectrum in genetically defined inbred strains. Hum Pathol 16:671&#x2013;673. 10.1016/s0046-8177(85)80149-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0046-8177(85)80149-0</ArticleId><ArticleId IdType="pubmed">2989148</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman AM, McNamara D. 2000. Myocarditis. N Engl J Med 343:1388&#x2013;1398. 10.1056/NEJM200011093431908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200011093431908</ArticleId><ArticleId IdType="pubmed">11070105</ArticleId></ArticleIdList></Reference><Reference><Citation>Modlin JF. 1980. Fatal echovirus 11 disease in premature neonates. Pediatrics 66:775&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">7432883</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostoufizadeh M, Lack EE, Gang DL, Perez-Atayde AR, Driscoll SG. 1983. Postmortem manifestations of echovirus 11 sepsis in five newborn infants. Hum Pathol 14:818&#x2013;823. 10.1016/s0046-8177(83)80304-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0046-8177(83)80304-9</ArticleId><ArticleId IdType="pubmed">6885039</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadare G, Haenni AL. 1997. Virus-encoded RNA helicases. J Virol 71:2583&#x2013;2590. 10.1128/JVI.71.4.2583-2590.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.71.4.2583-2590.1997</ArticleId><ArticleId IdType="pmc">PMC191378</ArticleId><ArticleId IdType="pubmed">9060609</ArticleId></ArticleIdList></Reference><Reference><Citation>Raney KD, Byrd AK, Aarattuthodiyil S. 2013. Structure and mechanisms of SF1 DNA helicases. Adv Exp Med Biol 973:E1. 10.1007/978-1-4614-5037-5_14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4614-5037-5_14</ArticleId><ArticleId IdType="pubmed">23269543</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairman-Williams ME, Guenther UP, Jankowsky E. 2010. SF1 and SF2 helicases: family matters. Curr Opin Struct Biol 20:313&#x2013;324. 10.1016/j.sbi.2010.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2010.03.011</ArticleId><ArticleId IdType="pmc">PMC2916977</ArticleId><ArticleId IdType="pubmed">20456941</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton MR, Dillingham MS, Wigley DB. 2007. Structure and mechanism of helicases and nucleic acid translocases. Annu Rev Biochem 76:23&#x2013;50. 10.1146/annurev.biochem.76.052305.115300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.76.052305.115300</ArticleId><ArticleId IdType="pubmed">17506634</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Cheng Z, Zhang S, Xiong W, Xia H, Qiu Y, Wang Z, Wu F, Qin CF, Yin L, Hu Y, Zhou X. 2014. A cypovirus VP5 displays the RNA chaperone-like activity that destabilizes RNA helices and accelerates strand annealing. Nucleic Acids Res 42:2538&#x2013;2554. 10.1093/nar/gkt1256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1256</ArticleId><ArticleId IdType="pmc">PMC3936753</ArticleId><ArticleId IdType="pubmed">24319147</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee NR, Kwon HM, Park K, Oh S, Jeong YJ, Kim DE. 2010. Cooperative translocation enhances the unwinding of duplex DNA by SARS coronavirus helicase nsP13. Nucleic Acids Res 38:7626&#x2013;7636. 10.1093/nar/gkq647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq647</ArticleId><ArticleId IdType="pmc">PMC2995068</ArticleId><ArticleId IdType="pubmed">20671029</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu T, Huang M, Wu D, Ren Y, Zhang X, Han Y, Mu J, Wang R, Qiu Y, Zhang DY, Zhou X. 2020. SARS-coronavirus-2 Nsp13 possesses NTPase and RNA helicase activities that can be inhibited by bismuth salts. Virol Sin 35:321&#x2013;329. 10.1007/s12250-020-00242-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00242-1</ArticleId><ArticleId IdType="pmc">PMC7271831</ArticleId><ArticleId IdType="pubmed">32500504</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick DN. 2007. The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. Curr Issues Mol Biol 9:1&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3571657</ArticleId><ArticleId IdType="pubmed">17263143</ArticleId></ArticleIdList></Reference><Reference><Citation>Li TF, Hosmillo M, Schwanke H, Shu T, Wang Z, Yin L, Curry S, Goodfellow IG, Zhou X. 2017. Human norovirus NS3 has RNA helicase and chaperoning activities. J Virol 92:e01606-17. 10.1128/JVI.01606-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01606-17</ArticleId><ArticleId IdType="pmc">PMC5809735</ArticleId><ArticleId IdType="pubmed">29237842</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpe YA, Aher PP, Lole KS. 2011. NTPase and 5'-RNA triphosphatase activities of Chikungunya virus nsP2 protein. PLoS One 6:e22336. 10.1371/journal.pone.0022336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0022336</ArticleId><ArticleId IdType="pmc">PMC3139623</ArticleId><ArticleId IdType="pubmed">21811589</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Han Y, Qiu Y, Zhang S, Tang F, Wang Y, Zhang J, Hu Y, Zhou X. 2012. Identification and characterization of RNA duplex unwinding and ATPase activities of an alphatetravirus superfamily 1 helicase. Virology 433:440&#x2013;448. 10.1016/j.virol.2012.08.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2012.08.045</ArticleId><ArticleId IdType="pmc">PMC7111927</ArticleId><ArticleId IdType="pubmed">22995190</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu T, Gan T, Bai P, Wang X, Qian Q, Zhou H, Cheng Q, Qiu Y, Yin L, Zhong J, Zhou X. 2019. Ebola virus VP35 has novel NTPase and helicase-like activities. Nucleic Acids Res 47:5837&#x2013;5851. 10.1093/nar/gkz340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz340</ArticleId><ArticleId IdType="pmc">PMC6582406</ArticleId><ArticleId IdType="pubmed">31066445</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi XG. 2007. Helicases as antiviral and anticancer drug targets. Curr Med Chem 14:883&#x2013;915. 10.2174/092986707780362998.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986707780362998</ArticleId><ArticleId IdType="pubmed">17430143</ArticleId></ArticleIdList></Reference><Reference><Citation>Lulla V, Dinan AM, Hosmillo M, Chaudhry Y, Sherry L, Irigoyen N, Nayak KM, Stonehouse NJ, Zilbauer M, Goodfellow I, Firth AE. 2019. An upstream protein-coding region in enteroviruses modulates virus infection in gut epithelial cells. Nat Microbiol 4:280&#x2013;292. 10.1038/s41564-018-0297-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0297-1</ArticleId><ArticleId IdType="pmc">PMC6443042</ArticleId><ArticleId IdType="pubmed">30478287</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfister T, Wimmer E. 1999. Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication. J Biol Chem 274:6992&#x2013;7001. 10.1074/jbc.274.11.6992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.11.6992</ArticleId><ArticleId IdType="pubmed">10066753</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirzayan C, Wimmer E. 1994. Biochemical studies on poliovirus polypeptide 2C: evidence for ATPase activity. Virology 199:176&#x2013;187. 10.1006/viro.1994.1110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1994.1110</ArticleId><ArticleId IdType="pubmed">8116241</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H, Wang P, Wang GC, Yang J, Sun X, Wu W, Qiu Y, Shu T, Zhao X, Yin L, Qin CF, Hu Y, Zhou X. 2015. Human enterovirus nonstructural protein 2CATPase functions as both an RNA helicase and ATP-independent RNA chaperone. PLoS Pathog 11:e1005067. 10.1371/journal.ppat.1005067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005067</ArticleId><ArticleId IdType="pmc">PMC4517893</ArticleId><ArticleId IdType="pubmed">26218680</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SH, Wang K, Zhao K, Hua SC, Du J. 2020. The structure, function, and mechanisms of action of enterovirus non-structural protein 2C. Front Microbiol 11:615965. 10.3389/fmicb.2020.615965.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.615965</ArticleId><ArticleId IdType="pmc">PMC7767853</ArticleId><ArticleId IdType="pubmed">33381104</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez PL, Carrasco L. 1993. Poliovirus protein 2C has ATPase and GTPase activities. J Biol Chem 268:8105&#x2013;8110. 10.1016/S0021-9258(18)53068-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)53068-4</ArticleId><ArticleId IdType="pubmed">8385138</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan H, Tian J, Qin B, Wojdyla JA, Wang B, Zhao Z, Wang M, Cui S. 2017. Crystal structure of 2C helicase from enterovirus 71. Sci Adv 3:e1602573. 10.1126/sciadv.1602573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.1602573</ArticleId><ArticleId IdType="pmc">PMC5409451</ArticleId><ArticleId IdType="pubmed">28508043</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidotti G, Brambilla L, Rossi D. 2017. Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol Sci 38:406&#x2013;424. 10.1016/j.tips.2017.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2017.01.003</ArticleId><ArticleId IdType="pubmed">28209404</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Song Z, Qin B, Zhang X, Chen L, Hu Y, Yuan Z. 2013. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Antiviral Res 97:264&#x2013;269. 10.1016/j.antiviral.2012.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.12.029</ArticleId><ArticleId IdType="pubmed">23295352</ArticleId></ArticleIdList></Reference><Reference><Citation>He QQ, Ren S, Xia ZC, Cheng ZK, Peng NF, Zhu Y. 2018. Fibronectin facilitates enterovirus 71 infection by mediating viral entry. J Virol 92:e02251-17. 10.1128/JVI.02251-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02251-17</ArticleId><ArticleId IdType="pmc">PMC5899198</ArticleId><ArticleId IdType="pubmed">29467312</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Wakita T, Shimizu H. 2008. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol 89:2518&#x2013;2530. 10.1099/vir.0.2008/002915-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/002915-0</ArticleId><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H, Agoh M, Agoh Y, Yoshida H, Yoshii K, Yoneyama T, Hagiwara A, Miyamura T. 2000. Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J Virol 74:4146&#x2013;4154. 10.1128/jvi.74.9.4146-4154.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.74.9.4146-4154.2000</ArticleId><ArticleId IdType="pmc">PMC111929</ArticleId><ArticleId IdType="pubmed">10756027</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma AM, Heggermont W, Lanke K, Coutard B, Bergmann M, Monforte AM, Canard B, De Clercq E, Chimirri A, Purstinger G, Rohayem J, van Kuppeveld F, Neyts J. 2008. The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J Virol 82:4720&#x2013;4730. 10.1128/JVI.01338-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01338-07</ArticleId><ArticleId IdType="pmc">PMC2346740</ArticleId><ArticleId IdType="pubmed">18337578</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q, Xu Z, Jin M, Shu T, Chen Y, Feng L, Zhang Q, Lan K, Wu S, Zhou HB. 2020. Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: in vitro, in vivo, and combination therapy study. Eur J Med Chem 202:112310. 10.1016/j.ejmech.2020.112310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2020.112310</ArticleId><ArticleId IdType="pubmed">32619885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L, Manganaro R, Zonsics B, Hurdiss DL, Zwaagstra M, Donselaar T, Welter NGE, van Kleef R, Lopez ML, Bevilacqua F, Raman T, Ferla S, Bassetto M, Neyts J, Strating J, Westerink RHS, Brancale A, van Kuppeveld FJM. 2020. Rational design of highly potent broad-spectrum enterovirus inhibitors targeting the nonstructural protein 2C. PLoS Biol 18:e3000904. 10.1371/journal.pbio.3000904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3000904</ArticleId><ArticleId IdType="pmc">PMC7673538</ArticleId><ArticleId IdType="pubmed">33156822</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Yu T, Ding Y, Li Y, Lei J, Hu B, Zhou J. 2020. Analysis of expression profiles of long noncoding RNAs and mRNAs in A549 cells infected with H3N2 swine influenza virus by RNA sequencing. Virol Sin 35:171&#x2013;180. 10.1007/s12250-019-00170-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-019-00170-9</ArticleId><ArticleId IdType="pmc">PMC7198687</ArticleId><ArticleId IdType="pubmed">31777011</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao M, Yu F, Wang D, Tong Y, Yang L, Xu J, Qiu Y, Zhou X, Zhao X. 2019. Proteomics profiling of host cell response via protein expression and phosphorylation upon dengue virus infection. Virol Sin 34:549&#x2013;562. 10.1007/s12250-019-00131-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-019-00131-2</ArticleId><ArticleId IdType="pmc">PMC6814695</ArticleId><ArticleId IdType="pubmed">31134586</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Z, Yang J, Xia H, Qiu Y, Wang Z, Han Y, Xia X, Qin CF, Hu Y, Zhou X. 2013. The nonstructural protein 2C of a picorna-like virus displays nucleic acid helix destabilizing activity that can be functionally separated from its ATPase activity. J Virol 87:5205&#x2013;5218. 10.1128/JVI.00245-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00245-13</ArticleId><ArticleId IdType="pmc">PMC3624285</ArticleId><ArticleId IdType="pubmed">23449794</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>